Drugs / anti-SLAMF7 CAR
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03958656 | Jun 2019 → Oct 2020 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-SLAMF7 CAR | “We have constructed a novel anti-SLAMF7 CAR that can specifically recognize SLAMF7- expressing target cells and eradicate SLAMF7-expressing tumors in mice.” NCT03958656 ↗ |
| Modality | Cell therapy | “T cells can be genetically modified to express chimeric antigen receptors (CARs) that target malignancy-associated antigens.” NCT03958656 ↗ |
| Route | Intravenous | “Participants will receive the manipulated T cells through the central line.” NCT03958656 ↗ |
| Target | SLAMF7 | “We have constructed a novel anti-SLAMF7 CAR that can specifically recognize SLAMF7- expressing target cells and eradicate SLAMF7-expressing tumors in mice.” NCT03958656 ↗ |